Literature DB >> 28706901

Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.

Kazunori Okabe1.   

Abstract

Malignant pleural mesothelioma (MPM) is a dreadful disease with a poor prognosis. Multimodality therapy including surgical macroscopic complete resection is performed to treat operable MPM. Intraoperative intracavitary hyperthermic chemotherapy for MPM was reviewed. Appropriate papers published between 2006 and present were extracted by the PubMed advanced search by MPM (Title/Abstract), chemotherapy (Title/Abstract), and hyperthermia (All fields). Among the selected papers, those written in English, and treated more than ten MPM patients were reviewed. The intraoperative intracavitary hyperthermic chemotherapy has been performed following extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) for MPM. Cisplatin was mainly used for perfusion, and the morbidity and mortality was acceptable. In conclusion, the intraoperative intracavitary hyperthermic chemotherapy following EPP or P/D for MPM might enhance local control in the chest cavity.

Entities:  

Keywords:  Chemotherapy; hyperthermia; mesothelioma; surgery

Year:  2017        PMID: 28706901      PMCID: PMC5497114          DOI: 10.21037/atm.2017.03.78

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  9 in total

1.  Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

Authors:  David J Sugarbaker; Ritu R Gill; Beow Y Yeap; Andrea S Wolf; Marcelo C DaSilva; Elizabeth H Baldini; Raphael Bueno; William G Richards
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-21       Impact factor: 5.209

2.  The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.

Authors:  Valerie Rusch; Elizabeth H Baldini; Raphael Bueno; Marc De Perrot; Raja Flores; Seiki Hasegawa; Walter Klepetko; Lee Krug; Loïc Lang-Lazdunski; Harvey Pass; Walter Weder; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-14       Impact factor: 5.209

3.  Perspective on malignant pleural mesothelioma diagnosis and treatment.

Authors:  Ori Wald; David J Sugarbaker
Journal:  Ann Transl Med       Date:  2016-03

4.  Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.

Authors:  William G Richards; Lambros Zellos; Raphael Bueno; Michael T Jaklitsch; Pasi A Jänne; Lucian R Chirieac; Beow Y Yeap; Rene J Dekkers; Phillip M Hartigan; Leah Capalbo; David J Sugarbaker
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

5.  Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.

Authors:  I Opitz; B Sigrist; S Hillinger; D Lardinois; R Stahel; W Weder; S Hopkins-Donaldson
Journal:  Lung Cancer       Date:  2007-03-23       Impact factor: 5.705

6.  A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.

Authors:  Lambros Zellos; William G Richards; Leah Capalbo; Michael T Jaklitsch; Lucian R Chirieac; Bruce E Johnson; Raphael Bueno; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 5.209

7.  Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.

Authors:  Tamara R Tilleman; William G Richards; Lambros Zellos; Bruce E Johnson; Michael T Jaklitsch; Jordan Mueller; Beow Yong Yeap; Aneil A Mujoomdar; Christopher T Ducko; Raphael Bueno; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 5.209

Review 8.  Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma.

Authors:  Aneil A Mujoomdar; David J Sugarbaker
Journal:  Semin Thorac Cardiovasc Surg       Date:  2008

9.  Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.

Authors:  Loïc Lang-Lazdunski; Andrea Bille; Sophie Papa; Stuart Marshall; Rohit Lal; Carlotta Galeone; David Landau; Jeremy Steele; James Spicer
Journal:  J Thorac Cardiovasc Surg       Date:  2014-10-14       Impact factor: 5.209

  9 in total
  2 in total

1.  Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities.

Authors:  Mikiko Nakanishi-Imai; Taro Murai; Masahiro Onishi; Atsuto Mouri; Takafumi Komiyama; Motoko Omura; Shigehiro Kudo; Akihiko Miyamoto; Masaru Hoshino; Shinichi Ogawa; Shizuko Ohashi; Masahiko Koizumi; Junichi Omagari; Hiroshi Mayahara; Katsuyuki Karasawa; Toshiyuki Okumura; Yuta Shibamoto
Journal:  J Radiat Res       Date:  2022-03-17       Impact factor: 2.724

2.  Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.

Authors:  Luca Ampollini; Elisabetta Barocelli; Andrea Cavazzoni; Piergiorgio Petronini; Claudio Mucchino; Anna Maria Cantoni; Fabio Leonardi; Luigi Ventura; Stefano Barbieri; Paolo Colombo; Antonella Fusari; Paolo Carbognani; Michele Rusca; Fabio Sonvico
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.